Table 2 Coverage of Zimbabwe national policies on HIV testing and counselling (HTC), prevention of mother to child transmission (PMTCT) and antiretroviral therapy (ART) care in 2013 and 2015

  Free HTC services

31 (86)

36 (100)

0.03

5 (100)

5 (100)

8 (80)

10 (100)

18 (86)

21 (100)

  PITC to ANC clients

34 (97)^a

35 (100)^a

N/A

5 (100)

5 (100)

10 (100)

10 (100)

19 (95)^a

20 (100)^a

  PITC to TB clients

36 (100)

34 (100)^a

N/A

5 (100)

5 (100)

10 (100)

9 (100)^a

21 (100)

20 (100)^a

  PITC to STI and FP clients

35 (100)^a

35 (100)^a

N/A

5 (100)

5 (100)

10 (100)

10 (100)

20 (100)^a

20 (100)^a

  Testing offered to sex workers

21 (60)^a

21 (58)

0.74

5 (100)

5 (100)

7 (78)^a

6 (60)

9 (43)

10 (48)

  Occurrence of at least one test-kit stock-out

25 (69)

22 (61)

0.44

5 (100)

4 (80)

7 (70)

4 (40)

13 (62)

14 (67)

  ≥ 1 staff member received HTC training in past 2 years

22 (63)^a

18 (50)

0.35

5 (100)

4 (100)

6 (60)

5 (50)

11 (55)^a

9 (43)

  Quality of care audit at least once a year

32 (91)^a

32 (89)

0.71

5 (100)

5 (100)

8 (80)

10 (100)

19 (95)^a

19 (81)

 Co-ordination of care and patient tracking

  Repeat test after 3-month period

35 (97)

26 (72)

0.01

4 (80)

4 (80)

10 (100)

6 (60)

21 (100)

16 (76)

 Support to PLHIV

  Pre-test counselling always provided

35 (97)

34 (94)

0.56

5 (100)

5 (100)

10 (100)

8 (80)

20 (95)

34 (94)

  Post-test counselling always provided

35 (97)

35 (97)

N/A

5 (100)

5 (100)

10 (100)

9 (90)

20 (95)

21 (100)

  Free PMTCT services

16 (44)

35 (97)

< 0.001

1 (20)

5 (100)

6 (60)

10 (100)

9 (44)

20 (95)

  Co-trimoxazole prophylaxis available and in stock

33 (92)

34 (97)^a

0.32

5 (100)

5 (100)

7 (70)

10 (100)

21 (100)

19 (95)^a

  Option B+

27 (79)^a

35 (100)^a

0.01

5 (100)

5 (100)

5 (56)^a

10 (100)

17 (85)^a

20 (100)^a

  PMTCT regimen (TDF, 3TC, EFV)

6 (18)^a

35 (100)^a

< 0.001

2 (40)

5 (100)

1 (13)^a

9 (100)^a

3 (14)

21 (100)

  Free ART services

29 (81)

36 (100)

0.01

3 (60)

5 (100)

8 (80)

10 (100)

18 (86)

21 (100)

  ART initiation at facility

14 (39)

35 (100)^a

< 0.001

5 (100)

5 (100)

4 (40)

10 (100)

5 (24)

20 (100)^a

  Quality of care audit at least once a year

36 (100)

34 (100)^a

N/A

5 (100)

4 (100)^a

10 (100)

10 (100)

21 (100)

20 (100)^a

  ≥ 1 staff member received HIV treatment training in past 2 years

9 (25)

19 (54)^a

0.01

4 (80)

4 (80)

2 (20)

3 (33)^a

3 (14)

12 (57)

  Drugs collectable by designee

14 (100)

32 (91)^a

0.32

5 (100)

5 (100)

4 (100)

10 (100)

5 (100)

17 (85)^a

  Home visits conducted following poor adherence

4 (27)

12 (34)^a

0.08

1 (20)

3 (60)

1 (25)

6 (60)

1 (20)

14 (70)^a

  Home visits conducted following missed visit

11 (85)^a

10 (29)

0.005

3 (75)^a

0 (0)

4 (100)

4 (40)

4 (80)

6 (30)^a

  Laboratory testing services offered

9 (64)^b

9 (26)

0.32

4 (80)

4 (80)

4 (100)

2 (20)

1 (20)^b

3 (15)

  Liver function tests conducted at facility

1 (7)

1 (3)

N/A

1 (20)

1 (20)

0 (0)

0 (0)

0 (0)

0 (0)

  Renal function tests conducted at facility

1 (7)

1 (3)

N/A

1 (20)

1 (20)

0 (0)

0 (0)

0 (0)

0 (0)

  HB/full blood count conducted at facility

7 (50)

7 (20)

0.32

4 (80)

4 (80)

2 (50)

0 (0)

1 (20)

3 (15)

  CD4 testing conducted at facility

6 (46)^a

6 (17)

N/A

4 (80)

4 (80)

2 (50)

2 (20)

0 (0)^a

0 (0)

  Nurse-led ART initiation

10 (71)

32 (100)^a

0.08

3 (60)

2 (100)^b

3 (75)

10 (100)

4 (80)

20 (100)

  WHO-recommended first-line regimen for non-pregnant adults

9 (64)

33 (94)

0.1

4 (80)

5 (100)

2 (50)

9 (90)

3 (60)

19 (95)

  6 monthly (min) CD4 on ART stable patients

14 (100)

35 (100)

N/A

5 (100)

5 (100)

4 (100)

10 (100)

5 (100)

20 (100)

  Prophylactic IPT in stock

11 (79)

15 (43)

0.41

5 (100)

5 (100)

3 (75)

3 (30)

3 (60)

7 (35)

  TB screening at every ART visit

12 (86)

35 (100)

0.16

3 (60)

5 (100)

4 (100)

10 (100)

5 (100)

20 (100)

  At least two first-line regimen choices available at facility

12 (92)^a

15 (43)

0.02

5 (100)

2 (40)

2 (67)^a

5 (50)

5 (100)

8 (40)

  Occurrence of at least one stock-out of first-line ART drugs

1 (7)

0 (0)^a

N/A

0 (0)

0 (0)

0 (0)

0 (0)

1 (20)

0 (0)

  Occurrence of at least one stock-out of OI drugs

4 (21)

2 (6)

0.65

0 (0)

1 (20)

2 (50)

0 (0)

1 (20)

1 (5)